Infinity Pharmaceuticals

Infinity Pharmaceuticals Stock-Based Compensation

The Stock-Based Compensation (SBC) of Infinity Pharmaceuticals (INFIQ) as of Nov 20, 2026 is 3.62 M USD. In the previous year, Stock-Based Compensation (SBC) was 2.70 M USD — a change of 34.36% (higher).

Stock-Based Compensation

3.62 MUSD

YoY

34.36%

Last updated:

Stock-Based Compensation (SBC) of Infinity Pharmaceuticals is 2022 3.62 M USD. Stock-Based Compensation (SBC) of Infinity Pharmaceuticals was 2021 2.70 M USD. It decreases by 34.36% higher compared to the previous year.

The Infinity Pharmaceuticals Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2015
14.70 M USD
Jan 1, 2016
13.71 M USD
Jan 1, 2017
6.97 M USD
Jan 1, 2018
3.45 M USD
Jan 1, 2019
2.13 M USD
Jan 1, 2020
1.46 M USD
Jan 1, 2021
2.70 M USD
Jan 1, 2022
3.62 M USD
The Infinity Pharmaceuticals Stock-Based Compensation history
YEARStock-Based CompensationYoY
3.62 MUSD+34.36%
2.70 MUSD+85.10%
1.46 MUSD-31.74%
2.13 MUSD-38.14%
3.45 MUSD-50.55%
6.97 MUSD-49.16%
13.71 MUSD-6.71%
14.70 MUSD+16.78%
12.59 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Infinity Pharmaceuticals Stock analysis

What does Infinity Pharmaceuticals do? Infinity Pharmaceuticals Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2001 and focuses on the discovery and development of novel therapies for cancer and other serious diseases. Infinity Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Infinity Pharmaceuticals stock

Stock-Based Compensation (SBC) of Infinity Pharmaceuticals is 3.62 M USD in 2022.

Stock-Based Compensation (SBC) of Infinity Pharmaceuticals changed from 2.70 M USD to 3.62 M USD, representing a 34.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Infinity Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Infinity Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Infinity Pharmaceuticals

All Key Metrics — Infinity Pharmaceuticals